Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Emergent BioSolutions Inc. entered into Purchase and Sale Agreement with Bavarian Nordic valued at Cash purchase price of $270 million, milestone payments of up to $80 million, and earnout payments o (effective 2023-02-15).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Bavarian Nordic
- Value
- Cash purchase price of $270 million, milestone payments of up to $80 million, and earnout payments o
- Effective
- 2023-02-15
Exact text from the filing
On February 15, 2023, Emergent BioSolutions Inc. (“Emergent”), through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc. (collectively the “Company”) entered into a Purchase and Sale Agreement (the “Definitive Agreement”) with Bavarian Nordic (“Bavarian”) for the sale of the Company’s travel health business (the “Business”), including rights to Vivotif®, the licensed typhoid vaccine, Vaxchora®, the licensed cholera vaccine, the development-stage chikungunya vaccine candidate CHIKV VLP, the Company’s manufacturing site in Bern, Switzerland and certain of its development facilities in San Diego, California (collectively, the “Business Sale”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Emergent BioSolutions Inc. entered into Consent, Limited Waiver, and Third Amendment to the Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and certain lenders valued at Consent to Business Sale; limited waiver of defaults related to financial covenants and going concer (effective 2023-02-14).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Wells Fargo Bank, National Association, as administrative agent, and certain lenders
- Value
- Consent to Business Sale; limited waiver of defaults related to financial covenants and going concer
- Effective
- 2023-02-14
Exact text from the filing
On February 14, 2023, the Company entered into a Consent, Limited Waiver, and Third Amendment to the Amended and Restated Credit Agreement (the “Credit Agreement Amendment”) among the Company, as borrower, certain subsidiaries of the Company, as guarantors, Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Administrative Agent”), and certain lenders party thereto.
View on SEC.gov